DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Mavrilimumab
Mavrilimumab
Evaluation of Antibody Properties and Clinically Relevant Immunogenicity
Collaborations on Imaging – the Medimmune’S Innovative Way
Study Protocol
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis) – Forecast and Market Analysis to 2023
Targeting GM-CSF in Rheumatoid Arthritis A.B
Immunfarmakológia Immunfarmakológia
The Two Tontti Tudiul Lui Hi Ha Unit
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Meta-Analysis of Safety of Granulocyte-Macrophage Colony- Stimulating Factor in the Treatment of Rheumatoid Arthritis Rami Diab MD, Mohinder Vindhyal MD
Efficacy and Safety of Namilumab, a Human Monoclonal Antibody Against Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
(INN) for Biological and Biotechnological Substances
A Randomised Phase Iib Study of Mavrilimumab, a Novel GM−CSF Receptor Alpha Monoclonal Antibody, in the Treatment of Rheumatoid Arthritis
INN Working Document 05.179 Update 2011
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Top View
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled Therapeutic Leadership; Spearheading Immunology Biologics
(INN) for Biological and Biotechnological Substances
Biologics for Rheumatoid Arthritis1
Annual Report 2
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
A Randomized Phase Iib Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
Mavrilimumab, a Human Monoclonal Antibody Ann Rheum Dis: First Published As 10.1136/Ard.2010.146225 on 25 May 2011
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
RCR21: Mavrilimumab
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
Delivering Value for Patients and Shareholders
Effectiveness of Mavrilimumab in Viral Infections Including SARS-Cov-2 Infection - a Brief Review
2020 ACR Convergence Study Sponsor Statements
Mavrilimumab
Unintended Immunological Consequences of Biologic Therapy
International Nonproprietary Names for Pharmaceutical Substances (INN)
Astrazeneca Development Pipeline
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
Treatment of Rheumatoid Arthritis with Biological Agents —As a Typical and Common Immune-Mediated Inflammatory Disease
14 June 2021 Aperto
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
2018 Annual Report
Antibody News You Should Know July 1 - 15, 2020
GM-CSF Targeted Immunomodulation Affects Host Response to M
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Spondyloarthritis
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Astrazeneca and Incyte Say IDO
GSK and the University of Manchester: Manchester Collaborative Centre for Inflammation Research - Translational Research Centre for Inflammatory Diseases
Spotlight on Mavrilimumab for the Treatment of Rheumatoid Arthritis: Evidence to Date
2016 Medicines in Development for Autoimmune Diseases
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Upcoming Biological Therapies in Systemic Lupus Erythematosus
Namilumab Or Infliximab Compared to Standard of Care in Hospitalised Patients with COVID-19 (CATALYST): a Phase 2 Randomised Adaptive Trial
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis